NCT04236115

Brief Summary

Ninety-five patients, aged between 16 and 70 years old, were included in this study. Patients were divided into two groups. Group one received Articaine 4% with 1:00.000 Adrenalines. Group two received Prilocaine with 3% Felypressin (0.03 I.U. per ml). Onset time of anaesthesia was objectively evaluated by using electronic pulp testing.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
95

participants targeted

Target at P50-P75 for phase_4

Timeline
Completed

Started Sep 2017

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 20, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 20, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 20, 2018

Completed
1.6 years until next milestone

First Submitted

Initial submission to the registry

January 15, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

January 22, 2020

Completed
Last Updated

January 22, 2020

Status Verified

January 1, 2020

Enrollment Period

7 months

First QC Date

January 15, 2020

Last Update Submit

January 21, 2020

Conditions

Keywords

Carticainedental extractioninjectionsprilocaine

Outcome Measures

Primary Outcomes (1)

  • Does articaine, rather than prilocaine, increase the success rate of anaesthesia for extraction of maxillary teeth

    to compare the anaesthetic performances of 3% prilocaine (the safest local anaesthetic) with 4 % articaine (the local anaesthetic with fastest onset time of action) when used for maxillary teeth extraction

    6 months

Study Arms (2)

Articaine 4% with 1:00.000 Adrenaline

ACTIVE COMPARATOR

if the patient was in articaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.

Drug: Articaine 4%Drug: Adrenalin

Prilocaine with 3% Felypressin (0.03 I.U. per ml)

ACTIVE COMPARATOR

if the patient was in prelocaine group, buccal infiltration technique was applied by inserting a short needle at the height of buccal sulcus along the long axis of the subject tooth for extraction.

Drug: Prilocain 3%Drug: Felypressin

Interventions

Articaine 4% is dental local anaesthetic agent

Articaine 4% with 1:00.000 Adrenaline

prilocaine is dental local anaesthetic agent

Prilocaine with 3% Felypressin (0.03 I.U. per ml)

adrenaline is a vasoconstrictor

Articaine 4% with 1:00.000 Adrenaline

Felypressin is a vasoconstrictor

Prilocaine with 3% Felypressin (0.03 I.U. per ml)

Eligibility Criteria

Age16 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • Patients have one or two upper teeth for extraction, subject tooth or its adjacent must be vital, healthy patient or patient with mild systemic diseases (class I or II according to American Society of Anesthesiology).

You may not qualify if:

  • Patients excluded from this study if they have allergy to local anaesthetic agents or need surgical, or multiple teeth extraction.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Taibah University

Madinah, 41311, Saudi Arabia

Location

Related Publications (1)

  • Gazal G. Does articaine, rather than prilocaine, increase the success rate of anaesthesia for extraction of maxillary teeth. Saudi J Anaesth. 2020 Jul-Sep;14(3):297-301. doi: 10.4103/sja.SJA_94_20. Epub 2020 May 30.

MeSH Terms

Interventions

EpinephrineFelypressin

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsLypressinVasopressinsPituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteins

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: double blinded randomised trial
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

January 15, 2020

First Posted

January 22, 2020

Study Start

September 20, 2017

Primary Completion

April 20, 2018

Study Completion

June 20, 2018

Last Updated

January 22, 2020

Record last verified: 2020-01

Data Sharing

IPD Sharing
Will share

it will be provided on demand

Shared Documents
STUDY PROTOCOL, SAP, CSR

Locations